Data from one-year liraglutide phase 3 study published in The Lancet
- Details
- Category: Novo Nordisk
Data from a 52-week phase 3 study (LEAD™ 3) of liraglutide, a once-daily human GLP-1 analogue, were published by The Lancet. The study showed that liraglutide, when taken alone, produces statistically significant and sustained improvements in blood sugar control in patients with early type 2 diabetes, as compared with glimepiride, a widely used oral antidiabetic drug.
US Court Denies Teva's Motion For Summary Judgment In Pulmicort Respules Patent Litigation
- Details
- Category: AstraZeneca
AstraZeneca today announced that the US District Court for the District of New Jersey has denied Teva's Motion for Summary Judgment of no infringement in the PULMICORT RESPULES (budesonide inhalation suspension) patent litigation.
Nycomed optimises its European manufacturing network
- Details
- Category: Nycomed
Nycomed has announced a new strategy for its European manufacturing network. The company will focus its European production at five dedicated centres of competence and five facilities for regional supply. To optimise utilisation, production from two Danish and the Finnish plant will be transferred to other sites.
Pfizer Launches New Medicine Safety Website for Healthcare Professionals and Patients
- Details
- Category: Pfizer
Pfizer Inc launches of a new interactive online educational resource designed to give healthcare professionals, medical students, patients, patient advocates and the general public more information about medicine safety, and, in turn, more confidence when making decisions about appropriate treatment options.
Novo Nordisk acquires intellectual property rights from Neose Technologies
- Details
- Category: Novo Nordisk
Novo Nordisk today announced that it has signed an agreement to acquire intellectual property rights from Neose Technologies Inc. related to Neose's proprietary GlycoPEGylation technology. The acquired rights are currently subject to a license from Neose for Novo Nordisk's development of GlycoPEGylated recombinant blood clotting factors FVIIa, FVIII and FIX.
Bayer HealthCare acquires German DIREVO Biotech AG
- Details
- Category: Bayer
Bayer HealthCare AG acquires the German biotech company DIREVO Biotech AG, Cologne. With the acquisition of the biotech company specialized in protein engineering, Bayer strengthens the research competence in biologicals of its pharmaceutical division Bayer Schering Pharma.
DHL COLDCHAIN offers fast, reliable and flexible solutions designed for the Life Science Industry
- Details
- Category: Business
The life science industry increasingly demands for Europe-wide transport solutions which are able to guarantee product integrity. Being able to offer this, strengthens a global market position. Thus, DHL Freight has been developing the unique DHL COLDCHAIN network.
More Pharma News ...
- Bayer Intensifies Research in Early Diagnosis of Alzheimer's Disease
- Pfizer Will Withdraw Global Marketing Applications for Dalbavancin to Conduct a New Trial
- New low-dose oral contraceptive YAZ® launched in Europe
- Novo Nordisk launches a next generation of FlexPen®
- Pfizer and Medivation Enter into Global Agreement to Co-Develop and Market Dimebon
- TRANSCEND® trial confirms long-term protective benefits and excellent tolerability profile
- Anavex completes successful preclinical studies on lead Alzheimer's drug candidate